Who
Rosemary A. Crane
Director
Company insider
Files Form 4 as: Director, Teva Pharmaceutical Industries; Director, Certara; Director, Tarsus Pharmaceuticals; Director, Catalent; Director, PDS Biotechnology; CEO and President, Mela Sciences, Inc. /ny; President & CEO, Epocrates; Director, Targanta Therapeutics.
In numbers
- Trades disclosed
- 76
- Buys
- 1
- Sells
- 1
- Bought
- $50K
- Sold
- $34K
- Companies
- 8
- Companies where not an officer
- 6
- First trade
- 25 Aug 2008
- Last trade
- 5 Jun 2026
- Last filed
- 8 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Jun 2026filed 8 Jun 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | —14,492 | filing |
| 5 Jun 2026filed 8 Jun 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —14,492 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —14,492 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | —14,492 | filing |
| 28 May 2026filed 1 Jun 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —7,242 at $0.00 | filing |
| 28 May 2026filed 1 Jun 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —7,242 at $0.00 | filing |
| 14 May 2026filed 15 May 2026 | CERT CertaraSoftware | SEC FORM 4 Code M | —15,757 at $0.00 | filing |
| 14 May 2026filed 15 May 2026 | CERT Certaraoption or derivative · Software | SEC FORM 4 Code M | —15,757 at $0.00 | filing |
| 14 May 2026filed 15 May 2026 | CERT Certaraoption or derivative · Software | SEC FORM 4 Code M | —15,757 at $0.00 | filing |
| 14 May 2026filed 15 May 2026 | CERT CertaraSoftware | SEC FORM 4 Code M | —15,757 at $0.00 | filing |
| 6 Jun 2025filed 9 Jun 2025 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —9,632 at $0.00 | filing |
| 6 Jun 2025filed 9 Jun 2025 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | —9,632 | filing |
| 5 Jun 2025filed 9 Jun 2025 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —14,492 at $0.00 | filing |
| 21 May 2025filed 22 May 2025 | CERT Certaraoption or derivative · Software | SEC FORM 4 Code M | —11,928 at $0.00 | filing |
| 21 May 2025filed 22 May 2025 | CERT Certaraoption or derivative · Software | SEC FORM 4 Code A | —15,757 at $0.00 | filing |
| 21 May 2025filed 22 May 2025 | CERT CertaraSoftware | SEC FORM 4 Code M | —11,928 at $0.00 | filing |
| 24 Jun 2024filed 25 Jun 2024 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,350 at $0.00 | filing |
| 24 Jun 2024filed 25 Jun 2024 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —3,350 | filing |
| 15 Jun 2024filed 17 Jun 2024 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —21,108 at $0.00 | filing |
| 15 Jun 2024filed 17 Jun 2024 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | —21,108 | filing |
News
Comparing Harrow (NASDAQ:HROW) & Teva Pharmaceutical Industries (NYSE:TEVA)TEVA · tickerreport.com · 16 Oct 2026Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $50.00TEVA · dailypolitical.com · 15 Oct 2026Analyzing Astrazeneca (NYSE:AZN) & Teva Pharmaceutical Industries (NYSE:TEVA)TEVA · tickerreport.com · 13 Oct 2026
0 headlines in the last 90 days name Rosemary A. Crane; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.